The University of Sussex has issued a press release emphasising the exciting potential of TexRAD for aiding treatment decisions for patients with bowel cancer. The full article can be found here:
Dr Balaji Ganeshan of Texrad Limited will be presenting three Texrad papers during the scientific programme at the 100th conference of the Radiological Society of North America in Chicago which takes place 30 November to 5 December 2014.
Sun Nov 30 2014 11:15AM – 11:25AM ROOM E450A – MRI Tumor heterogeneity as a potential prognostic imaging biomarker in patients with rectal cancer treated with neoadjuvant chemoradiotherapy – presented by Dr Balaji Ganeshan
Sun Nov 30 2014 11:35AM – 11:45AM ROOM E450A – Performance of Texture Analysis, Diffusion Weighted Imaging and Perfusion Imaging in Predicting Tumoral Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients Studied with 3T MR – presented by Dr Balaji Ganeshan
Thu Dec 04 2014 11:10AM – 11:20AM ROOM E350 – PETCT derived tumoural heterogeneity and glucose uptake predicts survival in primary colorectal cancer patients – presented by Dr Balaji Ganeshan
Following on from the success of winning the SEHTA regional award Read more
A research group at the Institute of Nuclear Medicine, University College London Hospitals, Miles et al recently published an Read more
Texrad are proud to announce that we have won the Read more